Regeneron Pharmaceuticals, Inc. (REGN)

Environment story

Disclosed filings (10-K, proxy) contain no quantified Scope 1, 2, or 3 emissions data, no stated net-zero target year, and no disclosed renewable electricity percentage. In the absence of disclosure, Scope 3 is treated as undisclosed (rising-emissions-equivalent penalty) and the net-zero target is treated as absent, each triggering a 15-point deduction. No verified physical decarbonization infrastructure investments or resource-related controversies (toxic waste, excessive water use) were identified in the source documents, resulting in no additional adjustment in either direction. Facility expansion capital expenditures in Tarrytown, NY and Saratoga Springs, NY are for manufacturing capacity, not confirmed as decarbonization-specific infrastructure.

Social story

Source documents do not disclose a CEO-to-median-worker pay ratio, workforce turnover rate, or evidence of union-suppression activity, strikes, or NLRB complaints in the review period. Board-level gender diversity is approximately 31% (4 of 13 director nominees/members are women), which is at or slightly above the 30% threshold used in this rubric, so no diversity-related deduction applies. No supply-chain human-rights audit findings (e.g., cobalt/lithium mining exposure) were identified, consistent with Regeneron's biotechnology/pharmaceutical business model, which has limited raw-material extraction exposure. Average headcount grew from 14,383 (2024) to 15,261 (2025).

Governance story

Regeneron maintains a dual-class share structure (Common Stock and Class A Stock), triggering a 20-point deduction under this rubric's unequal-voting-rights criterion; the proxy statement itself references shareholder scrutiny of long-tenured leadership and board structure. Board independence is approximately 84.6% (11 of 13 directors), above the 75% threshold, so no independence-related deduction applies. No disclosed lobbying expenditures specifically targeting climate or consumer-protection deregulation were found in the source documents. However, the 10-K discloses ongoing civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts (referenced in Note 16), constituting an active government regulatory proceeding, resulting in a governance deduction. Litigation between Regeneron and Sanofi over Antibody Collaboration Agreement obligations (audit rights and information access) is also noted as an active legal dispute, though this is characterized as a commercial/contractual matter rather than a regulatory-fraud proceeding.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Regeneron Pharmaceuticals, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Regeneron Pharmaceuticals, Inc. in the app for interactive charts and portfolio building.

More in Healthcare